UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 343

Sortiert nach

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

The lancet oncology, 2010, Vol.11 (1), p.21-28

2010

Link zum Volltext

Verfügbarkeit prüfen

Raf: A Strategic Target for Therapeutic Development Against Cancer

Journal of clinical oncology, 2005-09, Vol.23 (27), p.6771-6790

2005

Link zum Volltext

Verfügbarkeit prüfen

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

Annual review of medicine, 2004-01, Vol.55 (1), p.433-457

Rowinsky, Eric K

2004

Link zum Volltext

Verfügbarkeit prüfen

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 2006-02, Vol.354 (6), p.567-578

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

Journal of clinical oncology, 2010-02, Vol.28 (5), p.780-787

2010

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Investigational new drugs, 2011-10, Vol.29 (5), p.1029-1037

2011

Link zum Volltext

Verfügbarkeit prüfen

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Journal of clinical oncology, 2004-08, Vol.22 (16), p.3238-3247

2004

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-01, Vol.15 (2), p.723-730

2009

Link zum Volltext

Verfügbarkeit prüfen

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Journal of clinical oncology, 2006-10, Vol.24 (30), p.4914-4921

2006

Link zum Volltext

Verfügbarkeit prüfen

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Blood, 2014-07, Vol.124 (3), p.385-392

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Investigational new drugs, 2020-10, Vol.38 (5), p.1448-1453

2020

Link zum Volltext

Verfügbarkeit prüfen

Targeting the molecular target of rapamycin (mTOR)

Current opinion in oncology, 2004-11, Vol.16 (6), p.564-575

Rowinsky, Eric K

2004

Link zum Volltext

Verfügbarkeit prüfen

IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor

Clinical cancer research, 2007-09, Vol.13 (18), p.5549s-5555s

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

Journal of clinical oncology, 2008-01, Vol.26 (3), p.361-367

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)

Journal of clinical oncology, 2003-02, Vol.21 (4), p.588-592

2003

Link zum Volltext

Verfügbarkeit prüfen

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

Clinical cancer research, 2006-10, Vol.12 (19), p.5755-5763

2006

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2009-06, Vol.15 (12), p.4207-4212

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2001-07, Vol.19 (13), p.3267-3279

2001

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese

Journal of clinical oncology, 2007-10, Vol.25 (30), p.4707-4713

2007

Link zum Volltext

Verfügbarkeit prüfen

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Journal of clinical oncology, 2002-05, Vol.20 (9), p.2240-2250

2002

Link zum Volltext

Verfügbarkeit prüfen

Quality of Life in Head and Neck Cancer Patients After Treatment With High-Dose Radiotherapy Alone or in Combination With Cetuximab

Journal of clinical oncology, 2007-06, Vol.25 (16), p.2191-2197

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2505-2512

2006

Link zum Volltext

Verfügbarkeit prüfen

Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy

Clinical cancer research, 2007-09, Vol.13 (18), p.5544s-5548s

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 343

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(320)
Mit Volltextzugriff
(331)

Publikationsform

Sprache

Englisch
(343)
Japanisch
(39)

Erscheinungsjahr

n.n

Thema

Humans
(237)
Life Sciences & Biomedicine
(203)
Oncology
(203)
Science & Technology
(203)
Biological And Medical Sciences
(176)
Medical Sciences
(176)
Antineoplastic Agents
(153)
Pharmacology. Drug Treatments
(152)
Female
(149)
Male
(139)
Middle Aged
(137)
Aged
(130)
Adult
(129)
Neoplasms - Drug Therapy
(109)
Chemotherapy
(101)
Dose-Response Relationship, Drug
(73)
Drug Administration Schedule
(57)
Tumors
(53)
Antineoplastic Agents - Therapeutic Use
(50)
Antineoplastic Agents - Adverse Effects
(43)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(68)
Clinical Cancer Research
(67)
Blood
(20)
Cancer Research
(20)
Cancer Chemotherapy And Pharmacology
(16)
Investigational New Drugs
(16)
Jnci : Journal Of The National Cancer Institute
(13)
Seminars In Oncology
(8)
Cancer
(7)
Anti-Cancer Drugs
(6)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

Raf: A Strategic Target for Therapeutic Development Against Cancer

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Targeting the molecular target of rapamycin (mTOR)

IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Quality of Life in Head and Neck Cancer Patients After Treatment With High-Dose Radiotherapy Alone or in Combination With Cetuximab

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy

Suchergebnisse filtern